US Prostate cancer Market

ID: MRFR/Pharma/12067-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Prostate Cancer Market Research Report By Type (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy, Diagnosis) and By End-User (Specialty Centers, Hospital & Clinics) - Growth & Industry Forecast 2025 To 2035
US Prostate cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.54%
2024 Market Size$ 1,560 Million
2025 Market Size$ 1,677.62 Million
2035 Market Size$ 3,470 Million
Key Players
Astellas Pharma
Bayer AG
Johnson & Johnson
Pfizer Inc
Merck & Co
Novartis AG
Opportunities
  • Increasing Incidence Rates
  • Rising Awareness and Education
  • Investment in Research and Development
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Type (USD Million)
      1. 4.1.1 Prostatic Adenocarcinoma
      2. 4.1.2 Small Cell Carcinoma
    2. 4.2 Life Sciences, BY Component (USD Million)
      1. 4.2.1 Therapy
      2. 4.2.2 Diagnosis
    3. 4.3 Life Sciences, BY End User (USD Million)
      1. 4.3.1 Specialty Centers
      2. 4.3.2 Hospital & Clinics
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Astellas Pharma (JP)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bayer AG (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Johnson & Johnson (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer Inc (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis AG (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bristol-Myers Squibb (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Amgen Inc (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY COMPONENT
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
    8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    11. 6.11 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
    12. 6.12 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 LIFE SCIENCES, BY COMPONENT, 2024 (% SHARE)
    14. 6.14 LIFE SCIENCES, BY COMPONENT, 2024 TO 2035 (USD Million)
    15. 6.15 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
    16. 6.16 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY COMPONENT, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Prostate cancer Market Segmentation

US Prostate cancer Market By Type (USD Million, 2025-2035)

  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma

US Prostate cancer Market By Component (USD Million, 2025-2035)

  • Therapy
  • Diagnosis

US Prostate cancer Market By End User (USD Million, 2025-2035)

  • Specialty Centers
  • Hospital & Clinics
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.